People · Operator
Named in public records as an officer, director or promoter · active 2010–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| bluebird bio, Inc. | — | Biotechnology | Series C | $187.5M | $1.9B | 2010 |
| Exosome Diagnostics, Inc. | — | Biotechnology | Series B | $90.9M | $1.2B | 2010 |
Geert-Jan Mulder at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Geert-Jan Mulder on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Robert Tepper | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| Nick Leschly | 1 | 5 |
| William Kelly | 1 | 5 |
| Georg Nebgen | 1 | 5 |
| David Okrongly | 1 | 4 |
| Chip Baird | 1 | 4 |
| John Boyce | 1 | 4 |
| James McCullough | 1 | 3 |
| James A. Geraghty | 1 | 3 |
| Sara Barrington | 1 | 3 |
| Kapil Dhingra | 1 | 2 |
| Thomas McLain | 1 | 2 |
| Peter Johann | 1 | 2 |
| Joseph Boystak | 1 | 2 |
| Denice R. Torres | 1 | 2 |
| William R. Sellers | 1 | 2 |
| Dhingra Kapil | 1 | 1 |
| Joseph Slattery | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.